Podrobno

Načrtovanje, sinteza in vrednotenje kvarternih dušikovih heterociklov kot fragmentov za ciljanje mitohondrijev
ID Džajić, Ivan (Avtor), ID Cotman, Andrej Emanuel (Mentor) Več o mentorju... Povezava se odpre v novem oknu, ID Peterlin Mašič, Lucija (Komentor)

.pdfPDF - Predstavitvena datoteka, prenos (12,02 MB)
MD5: CB8BFFEE22DB3F7C0F57C529E90E3A97

Izvleček
Mitohondrijsko usmerjana (MT) terapija predstavlja del širšega področja organelno usmerjanih terapij v personalizirani medicini. Akumulacija trifenilfosfonijevega kationa (TPP⁺) v mitohondrijih, povezana z negativnim mitohondrijskim membranskim potencialom, je bila odkrita v 1970-ih letih. Pripenjanje TPP+ na raznolike funkcionalne molekulske tovore ga je uveljavilo kot »zlati standard« fragmentov za ciljanje mitohondrijev (MTM). Obetaven pristop za MT proti-rakavo terapijo vključuje uporabo MTM kot nosilcev za dostavo proti-rakavih učinkovin v mitohondrije in s tem zmanjšanje netarčnega delovanja. PAPTP je sestavljen iz TPP+ in zaviralca napetostno odvisnega kalijevega kanalčka (Kv1.3i) PAP-1. Učinkovito inducira apoptozo v kemorezistentnih rakavih celicah. Čeprav je TPP+ kanonični MTM, njegovo intrinzično zaviranje mitohondrijskih funkcij motivira razvoj alternativ z manj lastne biološke aktivnosti. Raziskave v tej doktorski disertaciji so bile usmerjene na študij lipofilnih kationskih N-povezanih dušikovih heterociklov kot MTM, z Kv1.3i kot modelnim tovorom. Cilji so bili odkriti katione z zmanjšano intrinzično bioaktivnostjo, primerljivo sposobnostjo MT kot TPP+ in izboljšanimi fizikalnokemijskimi lastnostmi, ter razširiti uporabo MTM na konjugate z zaviralcem Na+/Ca2+ izmenjevalca (NCLXi). MTM smo vrednotili kot konjugate s fluorescenčnim, funkcionalnim in inertnim tovorom, da bi ločeno vrednotili mitohondrijsko akumulacijo, terapevtski potencial in lastno bioaktivnost MTM. Sintetizirali in okarakterizirali smo knjižnico petdesetih kvarternih dušikovih kationov. Vrednotili smo jih prek fizikalnokemijskih, računskih, strukturnih in celičnih študij. Ključno odkritje je 3,5-difenilpiridinijev kation, ki je izolipofilen TPP+, in izkazuje zmanjšano toksičnost ter izboljšano protirakavo selektivnost v 2D in 3D modelih. Izpostavljamo še dva druga konjugata MTM–Kv1.3i – 2,3,5-trimetilpiridinijev in 3,5-dimetil-2-ciklopropilpiridinijev. Izkazujeta izboljšano termodinamsko topnost in sta signifikantno zmanjšala rast tumorja v primerjavi z vehikelsko kontrolo in vivo. Ta konceptualni okvir smo uporabili za pripravo petih novih konjugatov MTM–NCLXi, vključno s 3,5-difenilpiridinijevim konjugatom. Raziskave v sklopu tega dela vzpostavljajo temelje za prihodnji razvoj MTM in translacijo na druga področja raziskav mitohondrijev.

Jezik:Slovenski jezik
Ključne besede:mitohondrijsko usmerjanje, ionski kanali, rak, organelno usmerjena terapija.
Vrsta gradiva:Doktorsko delo/naloga
Tipologija:2.08 - Doktorska disertacija
Organizacija:FFA - Fakulteta za farmacijo
Založnik:[I. Džajić]
Leto izida:2026
PID:20.500.12556/RUL-190803 Povezava se odpre v novem oknu
UDK:615:54(043.3)
COBISS.SI-ID:304768003 Povezava se odpre v novem oknu
Datum objave v RUL:04.11.2026
Število ogledov:122
Število prenosov:33
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Design, synthesis, and evaluation of quaternary nitrogen heterocycles as mitochondria-targeting moieties
Izvleček:
Mitochondria-targeted (MT) therapy represents a part of a broader field of organelle-targeted therapies in precision medicine. The mitochondrial accumulation of the triphenylphosphonium cation (TPP+) was discovered in the 1970s, and it was related to the negative mitochondrial membrane potential in mitochondria. “Mitochondria-targeting moiety” (MTM) refers to the cationic part of a molecule linked to functional cargo with the intent to deliver it to the mitochondria. Since its discovery, the widespread use of TPP+ as an MTM has established it as a “gold standard” moiety. The implications of the Warburg phenomenon (namely about uniformly dysfunctional mitochondria in malignant cells) have previously ruled out the potential for MT cancer therapy research. However, more recent studies suggest that several cancer types retain functional mitochondria, making them suitable targets for MT therapy. In 2025, elamipretide and dordaviprone gained regulatory approval as the first therapeutics designed to target mitochondrial biology. Although the latter also targets the dopamine receptor, it is the first approved anti-cancer drug to include a mitochondrial target. A promising approach for MT anti-cancer therapy involves using MTMs as carriers to deliver selective anti-cancer agents to mitochondria and minimize off-target interactions, especially in cancer cell types with a more negative mitochondrial membrane potential. PAPTP is composed of TPP+ and a voltage-gated potassium channel inhibitor (Kv1.3i) PAP-1, shown to selectively induce apoptosis in chemoresistant cancer cells. However, it has been shown that TPP+ is not an inert carrier responsible for mitochondrial delivery, but it also causes uncoupling and respiratory chain inhibition. Consequently, a body of research is emerging in the search for a more inert TPP+ surrogate capable of MT delivery with minimized bioactivity separate from the effects of the functional cargo delivered. The research in this doctoral study was focused on exploring lipophilic cationic N-tethered nitrogen heterocycles as MTMs. The goals were to produce cations with reduced intrinsic bioactivity and MT capabilities similar to TPP+, MTMs with improved physicochemical properties, and widen the scope of MTM application by producing conjugates of MTMs and a Na+/Ca2+ exchanger (NCLX) inhibitor. The approach included design, synthesis and evaluation of conjugates of MTMs with three different types of cargo: fluorescent cargo (evaluation of mitochondrial accumulation), functional cargo (validated inhibitors of mitochondrial ion channels), and “inert” cargo (evaluation of bioactivity of the MTMs). We have conceptually proposed this tripartite approach in a perspective article, and then operationalized it in a research article, which is the first time a formalized approach was applied to the design and evaluation of novel MTMs. A large library of fifty quaternary nitrogen-based MTMs has been synthesized and characterized. All of the novel conjugates of ion channel inhibitors and MTMs have been evaluated in viability (metabolism and cell membrane disruption) assays and their water/1-octanol distribution coefficients, as well as thermodynamic solubilities have been determined. A subset of MTMs has been included in a crystallography study to further explore the structural and electronic characteristics of the novel moieties, to potentially find correlations with biological assays and aid future MTM design. The charge distribution of multiple MTMs has been screened using computational techniques and descriptors, such as maximum positive surface potential and molecular polarity index, have been calculated. A key discovery is the 3,5-diphenylpyridinium (DPPy) cation, isolipophilic to the TPP+, with proof of reduced toxicity and improved cancer selectivity in 2D and 3D models. Two other MTMs are highlighted – 2,3,5-trimethylpyridinium, and 3,5-dimethyl-2-cyclopropylpyridinium, and the two were shown to have greatly improved thermodynamic solubility, as well as to significantly reduce tumour growth relative to the vehicle control in vivo, when tethered to bioactive cargo. The knowledge gathered throughout the research of MTM–Kv1.3i conjugates was applied to prepare five novel MTM–NCLX inhibitor conjugates, one of which contained DPPy as the MTM. It is our expectation that this knowledge will be translated to other fields of MT research and that we have set a base for future MTMs to continue to develop.

Ključne besede:mitochondria targeting, ion channels, cancer, organelle-targeted therapy.

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj